BioAge Labs, Inc.
| Company Name | BioAge Labs, Inc. |
| Stock Symbol | BIOA |
| Class Period | September 26, 2024 to December 06, 2024 |
| Lead Plaintiff Motion Deadline | March 10, 2025 |
On or about September 26, 2024, BioAge conducted its IPO, selling 12.65 million shares of stock for $18 per share.
On December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag.
On this news, BioAge’s stock price declined $15.44 or 76.85% per share, to close at $4.65 per share on December 9, 2024.
The complaint filed in this class action alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies; (2) potential safety concerns with the Company’s ongoing STRIDES clinical trial; (3) that, as a result, the Company overstated the likelihood the ongoing STRIDES study would be completed; (4) that, as a result, the Company overstated the potential of a second Phase 2 clinical trial combining azelaprag and semaglutide to treat obesity in individuals ages 18 years and older; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Submit Your Information
If you suffered a loss on your BioAge Labs, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.